中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2009年
23期
1630-1632
,共3页
肺肿瘤%外科手术%药物疗法,联合
肺腫瘤%外科手術%藥物療法,聯閤
폐종류%외과수술%약물요법,연합
Lung neoplasms%Surgical procedures,operative%Drug therapy,combination
目的 研究术后化疗对Ⅰ期肺腺癌长期生存的影响.方法 收集1995年1月-2005年1月手术切除Ⅰ期(Ⅰ a+Ⅰ b)肺腺癌427例,比较术后化疗组与单纯手术组的治疗效果.结果Ⅰ a期1、3、5、10年生存率,术后化疗组为100.00%、92.34%、86.17%、74.82%.单纯手术组为96.63%、88.11%、79.52%、65.85%.Ⅰ b期1、3、5、10年生存率,术后化疗组为96.84%、77.99%、69.56%、64.36%.单纯手术组为85.65%、67.11%、59.56%、53.06%.Ⅰ a、Ⅰ b期术后化疗组与单纯手术组1年生存率比较差异均有统计学意义(P<0.05,P<0.01).结论 Ⅰ a和Ⅰ b术后化疗均比单纯手术预后好;Ⅰ期肺腺癌要取得较好的治疗效果,手术加术后化疗模式不可缺少.
目的 研究術後化療對Ⅰ期肺腺癌長期生存的影響.方法 收集1995年1月-2005年1月手術切除Ⅰ期(Ⅰ a+Ⅰ b)肺腺癌427例,比較術後化療組與單純手術組的治療效果.結果Ⅰ a期1、3、5、10年生存率,術後化療組為100.00%、92.34%、86.17%、74.82%.單純手術組為96.63%、88.11%、79.52%、65.85%.Ⅰ b期1、3、5、10年生存率,術後化療組為96.84%、77.99%、69.56%、64.36%.單純手術組為85.65%、67.11%、59.56%、53.06%.Ⅰ a、Ⅰ b期術後化療組與單純手術組1年生存率比較差異均有統計學意義(P<0.05,P<0.01).結論 Ⅰ a和Ⅰ b術後化療均比單純手術預後好;Ⅰ期肺腺癌要取得較好的治療效果,手術加術後化療模式不可缺少.
목적 연구술후화료대Ⅰ기폐선암장기생존적영향.방법 수집1995년1월-2005년1월수술절제Ⅰ기(Ⅰ a+Ⅰ b)폐선암427례,비교술후화료조여단순수술조적치료효과.결과Ⅰ a기1、3、5、10년생존솔,술후화료조위100.00%、92.34%、86.17%、74.82%.단순수술조위96.63%、88.11%、79.52%、65.85%.Ⅰ b기1、3、5、10년생존솔,술후화료조위96.84%、77.99%、69.56%、64.36%.단순수술조위85.65%、67.11%、59.56%、53.06%.Ⅰ a、Ⅰ b기술후화료조여단순수술조1년생존솔비교차이균유통계학의의(P<0.05,P<0.01).결론 Ⅰ a화Ⅰ b술후화료균비단순수술예후호;Ⅰ기폐선암요취득교호적치료효과,수술가술후화료모식불가결소.
Objective Observe the effect of operation plus post-operative chemotherapy for long-term results of stage Ⅰ lung adenocarcinorma. Methods From January 1994 to January 2005, 427 patients with stage Ⅰ lung adenocarcinorma underwent surgical resection therapy. The comparison of long-term survival rates was made between post-chemotherapy and surgical resection alone. Results The analyses disclosed that the stage Ⅰ a 1,3, 5 and 10-year survival rate of post-chemotherapy was 100.00%, 92.34%, 86.17% and 74.82%, respectively, while in surgical resection alone was 96.63%, 88.11%, 79.52% and 65.85%, respectively. The stage Ⅰ b 1, 3, 5 and 10-year survival rate of post-chemotherapy was 96.84%, 77.99%, 69. 56% and 64. 36%, respectively, while in surgical resection alone was 85.65% ,67.11%, 59.56% and 53.06%, respectively. There was statistically significant difference between 1 year survival rate of stage Ⅰ a patients with post-chemotherapy and those with surgical resection alone (P<0.05); 1 year survival rate of stage Ⅰ b patients with post-chemotherapy and those with surgical resection alone (P<0.01). Conclusion The operation plus post-operative chemotherapy is better than surgical resection alone in stage Ⅰ a and Ⅰ b. Surgical plus post-operative chemotherapy mode is indispensable for better prognosis of stage Ⅰ a and Ⅰ b lung adenocarcinorma.
